Product image of Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert Set

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Set, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed in fertility hormone therapy to address anovulation and to support controlled ovarian stimulation in assisted reproductive technologies.
GNH India supplies Meriofert Set as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Farmaceutici Italia

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert Set is a gonadotropin used in reproductive medicine to stimulate ovarian function.

  • Infertility due to anovulation: promotes follicular development and induces ovulation.
  • Controlled ovarian stimulation for assisted reproductive technologies: enhances follicle growth to optimize egg retrieval.
  • Ovulation induction in polycystic ovary syndrome: restores regular ovulatory cycles for conception.

How It Works

  • Follicle‑Stimulating Hormone and Luteinising Hormone bind to their respective FSH and LH receptors on ovarian granulosa and theca cells. This activation triggers intracellular signaling that promotes follicular maturation, estradiol synthesis, and the luteinising surge required for ovulation, thereby facilitating oocyte release for fertilisation.

Side Effects

Adverse reactions may occur with gonadotropin therapy and should be monitored.

Common Side Effects

  • Injection site pain or erythema: mild local discomfort after subcutaneous administration.
  • Abdominal discomfort or bloating: transient gastrointestinal sensations.
  • Nausea or mild headache: occasional systemic symptoms.
  • Mild ovarian hyperstimulation syndrome: ovarian enlargement with mild fluid shift.

Serious or Rare Side Effects

  • Severe ovarian hyperstimulation syndrome: marked ovarian enlargement, ascites, or thromboembolic complications.
  • Allergic reactions including anaphylaxis: rash, urticaria, respiratory distress.
  • Multiple pregnancy: increased risk of twins or higher‑order gestations.
  • Ectopic pregnancy: rare occurrence requiring prompt evaluation.

Precautions & Warnings

Careful patient assessment and monitoring are essential when using Meriofert Set.

  • Pregnancy testing: confirm non‑pregnant status before initiating therapy.
  • Ovarian monitoring: perform serial ultrasound to assess follicular response and prevent overstimulation.
  • Thromboembolic risk: evaluate history of clotting disorders before treatment.
  • Allergy assessment: screen for hypersensitivity to gonadotropin preparations.
  • Multiple pregnancy counseling: discuss the possibility of twins or higher‑order gestations.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential drug interactions may affect the efficacy or safety of Meriofert Set.

Major Interactions (Avoid)

  • GnRH antagonists: can diminish the stimulatory effect of FSH/LH therapy.
  • Oral contraceptives: suppress endogenous gonadotropin release, interfering with ovarian stimulation.
  • High‑dose estrogen therapy: may antagonize ovarian response to gonadotropins.

Moderate Interactions (Monitor Closely)

  • Thyroid hormone replacement: monitor thyroid function as gonadotropins can influence metabolism.
  • Anticoagulants: increased vigilance for thrombotic events during ovarian hyperstimulation.
  • Diuretics: may alter fluid balance during stimulation, requiring observation.

Frequently Asked Questions

Meriofert Set contains follicle‑stimulating hormone and luteinising hormone and is used in fertility hormone therapy to treat infertility caused by anovulation and to support controlled ovarian stimulation in assisted reproductive technologies such as in‑vitro fertilisation.

The two hormones bind to specific FSH and LH receptors on ovarian cells, activating signaling pathways that promote follicular growth, estradiol production and the luteinising surge that triggers ovulation, thereby facilitating the release of mature oocytes for fertilisation.

The dose of Meriofert Set is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian response, treatment protocol and clinical goals, and adjusts it according to monitoring results.

Meriofert Set is intended for use before conception to induce ovulation. It is not administered during an established pregnancy, and safety during breastfeeding has not been established, so use should be avoided in those situations unless specifically directed by a specialist.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Meriofert Set combines both FSH and LH activity in a single injectable, offering a convenient alternative to using separate FSH and LH preparations. This can simplify dosing schedules and may improve patient compliance compared with regimens that require multiple products.

Meriofert Set should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

The medication is supplied as a sterile solution for subcutaneous injection. It is typically administered by a healthcare professional or trained patient using a pre‑filled syringe or vial, following aseptic technique and the dosing schedule prescribed.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause significant fluid shifts and thromboembolic events, as well as rare allergic reactions such as anaphylaxis and the possibility of multiple or ectopic pregnancies, all of which require prompt medical attention.

Meriofert Set is contraindicated in patients with known hypersensitivity to gonadotropins, active ovarian cysts, uncontrolled thyroid disease, or a history of severe ovarian hyperstimulation syndrome. It should also be avoided in women who are already pregnant.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT